Mark Burkard is an Oncology physician affiliated with University of Iowa. OpenAlex indexes 440 publications with 7,005 citations (h-index 38); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Hawkins Dr
Iowa City, IA 522421009
Telephone
319-356-2353Provider last certified this registry record 18 Nov 2024.
Clinical trials
- Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
Sponsor: University of Wisconsin, Madison
- Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
Sponsor: University of Wisconsin, Madison
- Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer
Sponsor: University of Wisconsin, Madison
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
- PUMA BIOTECHNOLOGY, INC.Program year20242 payments
- Puma Biotechnology, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
91.7%Aromatase Inhibitor69.7%Anastrozole74%Letrozole21%Exemestane6%Part D<11 patientsEstrogen Agonist/Antagonist17%Tamoxifen Citrate100%Part D≥27 patients+ 1 more class in this area
Nervous system
3.3%Gabapentinoids3.3%Gabapentin100%Part D<11 patientsMetabolism & gastrointestinal
2.9%Serotonin-3 Receptor Antagonist2.9%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Lawrence Hunsicker, MD
University of Iowa
Brian Olshansky, MD
University of Iowa
Robert Weiss, MD
University of Iowa
Elliott Sohn, MD
University of Iowa
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”